PASG Passage Bio, Inc.
Healthcare$5.22+1.26%ClosedMarket Cap: $16.8M
As of 2026-05-25
Analyst Consensus
Consensus
Hold
Target (Consensus)
$10.00
Target (Median)
$8.00
Target Range
$7.00 - $15.00
Upside from current price: 91.4%
Rating Distribution
0 Strong Buy1 Buy4 Hold0 Sell0 Strong Sell
Recent Analyst Ratings
| Date | Firm | Action | Rating | Previous |
|---|---|---|---|---|
| 2026-04-21 | Chardan Capital | downgrade | Neutral | Buy |
| 2026-04-21 | Wedbush | downgrade | Neutral | Outperform |
| 2026-04-21 | Oppenheimer | maintain | Outperform | Outperform |
| 2026-04-21 | TD Cowen | downgrade | Hold | Buy |
| 2026-03-04 | Canaccord Genuity | maintain | Buy | Buy |
| 2025-11-12 | Chardan Capital | maintain | Buy | Buy |
| 2025-08-14 | Canaccord Genuity | maintain | Buy | Buy |
| 2025-08-14 | Guggenheim | maintain | Buy | Buy |
| 2025-08-13 | Wedbush | maintain | Outperform | Outperform |
| 2025-06-24 | Chardan Capital | maintain | Buy | Buy |
Forward Estimates
| Period | EPS Est. | Revenue Est. | # Analysts |
|---|---|---|---|
| Fri Dec 31 | $-7.84 | $45.0M | 3 |
| Sun Dec 31 | $-6.63 | $31.5M | 3 |
| Mon Dec 31 | $-7.07 | $15.0M | 1 |
| Tue Dec 31 | $-3.76 | $42.7M | 1 |